Document is current
Any future updates will be listed below
-
Authors
Koyama, Yoichi https://orcid.org/0000-0001-7435-1346
Muguruma, Masako https://orcid.org/0009-0006-2269-0411
Horimoto, Yoshiya https://orcid.org/0000-0001-8935-0768
Narui, Kazutaka https://orcid.org/0000-0002-0135-5001
Yamada, Akimitsu https://orcid.org/0000-0003-3006-0648
Yamada, Kimito https://orcid.org/0000-0002-5443-7078
Yamamoto, Shinya https://orcid.org/0000-0002-8083-5387
Orihara, Shunichiro https://orcid.org/0000-0003-0168-1250
Kaise, Hiroshi https://orcid.org/0000-0002-6638-783X
Kogure, Akiko
Yoshioka, Yusuke
Ochiya, Takahiro https://orcid.org/0000-0002-0776-9918
Ishikawa, Takashi https://orcid.org/0000-0003-3450-4533
-
Funding
Funding for this research was provided by:
Chugai Pharmaceutical (CGPS20230417008)
Nippon Kayaku (NKCS20230403003)
Taiho Pharmaceutical (AS2023A000703337)
Kyowa Kirin (KKCS20230412004)
- License Information
-
More Information
Article History
Received: 19 July 2025
Accepted: 6 September 2025
First Online: 29 September 2025
Declarations
:
: This study was approved by the Ethics Committee of Tokyo Medical University (Approval number; T2022-0044). All procedures involving human participants performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Due to the retrospective nature of the study, the requirement for informed consent was waived. The opportunity to refuse participation in the study was guaranteed by disclosing information about the research through a public announcement.
: The authors declare no competing interests.
